Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Astellas, LabCentral Partner to Help Emerging Biotechs Accelerate Research | Contract Pharma

What are you searching for?

Sign in
Breaking News

Astellas, LabCentral Partner to Help Emerging Biotechs Accelerate Research

Future Innovator Prize offers one-year use of LabCentral's state-of-the-art lab facility in Cambridge, MA and access to Astellas' R&D capabilities.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Astellas Venture Management LLC, a wholly-owned venture capital subsidiary of Astellas Pharma Inc., and LabCentral, a launchpad for early-stage life-sciences startups, have entered a collaboration on the “Future Innovator Prize” formerly known as the Astellas Golden Ticket Competition. The Future Innovator Prize offers entrepreneurial scientists or emerging biotech start-ups one-year use of LabCentral’s state-of-the-art lab facility in Cambridge, MA, as well as access to Astellas’ R&D capabilities and business leaders.
 
Astellas’ sponsorship of the Future Innovator Prize follows AVM obtaining Gold Sponsorship of LabCentral in October of 2019. Astellas and LabCentral work together to support scientists and early stage companies to accelerate their novel therapeutic programs, modalities or platforms.
 
“External innovation is critically important in helping us achieve our VISION of turning innovative science into VALUE for patients,” said Maruyama, President, AVM. “Combining our R&D capabilities and expertise with LabCentral’s established network and launchpad in the Boston area, we look to bring hope to patients worldwide by partnering with emerging biotechnology companies and transforming their ideas into reality.”
 
“We are extremely pleased to be working with Astellas to foster life-science innovation in the Boston area,” said Johannes Fruehauf, LabCentral Co-founder and President. “Our labs offer a fertile environment in which biotechnology visionaries can thrive by providing them with the space and resources they need to test out, challenge, and nurture early ideas. We are excited that Astellas has chosen to create the Future Innovator Prize program to supplement their external innovation initiatives.”

Read Contract Pharma’s Top Companies report on Asetellas Pharma.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics